Article Text

PDF
▼Acarbose for non-insulin-dependent diabetes mellitus

Abstract

Acarbose (Glucobay - Bayer) is the first in a new class of oral antidiabetic drugs, the α-glucosidase inhibitors. It is licensed for the treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM), either as first-line therapy when dietary measures are insufficient, or as an adjunct to conventional oral therapy where glycaemic control is suboptimal. The manufacturer claims that acarbose "can achieve a new level of blood glucose control in diabetes". In this article we consider whether acarbose offers any real advance.

Statistics from Altmetric.com

  • Relevant BNF section: 6.1.2.3

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.